Fort Myers, Fla., Sept. 17, 2021 (GLOBE NEWSWIRE) -- Florida Cancer Specialists & Research Institute (FCS) is well-represented at the European Society of Medical Oncology (ESMO) Congress, being held this week as a virtual experience. Four FCS physicians are the first authors and/or co-authors of five cancer research studies that will be presented. With over 20,000 members world-wide, the ESMO Congress gathers oncologists, researchers, patient advocates and pharmaceutical representatives to share the latest cutting-edge developments and findings.
The following FCS physician investigators will present their research results during poster discussions/presentations:
- Manish R. Patel, MD, Director of the FCS Drug Development Unit, first author of a study of monotherapy in patients with advanced solid tumors and co-author of a study involving the treatment of patients with advanced metastatic sarcoma.
- Faithlore Gardner, MD, first author of a Phase 2 study on metastatic pancreatic cancer and co-author of a study on gastroesophageal adenocarcinoma.
- Maen Hussein, MD, first author, and Ivor Percent, MD, co-author, of a study involving antibodies in previously treated advanced solid tumors.
FCS President and Managing Physician Lucio Gordan, MD said, “Our FCS Clinical Research Program continues to set a national benchmark for community oncology. We continue to expand access to a growing number of clinical trial opportunities, which means our patients receive the most promising new drugs and treatments available.”
“We are extremely proud that research done through our FCS Phase 1 Drug Development Units and at FCS clinics throughout Florida as part of our strategic partnership with Sarah Cannon is being shared on this prestigious global stage,” said Gustavo A. Fonseca, MD, FACP, FCS Director of Clinical Research. “We are particularly pleased with our ability to continue to advance care discoveries, despite the challenging circumstances of the COVID-19 pandemic.
The ESMO Congress 2021 is a global stage for the exchange of potentially practice-changing data and multidisciplinary conversations that will spur transformative therapies against cancer. All of the study abstracts will be published online in the ESMO Congress 2021 Abstract Book, a supplement to the official ESMO journal, Annals of Oncology.
# # #
About Florida Cancer Specialists & Research Institute
Recognized by the American Society of Clinical Oncology (ASCO) with a national Clinical Trials Participation Award, Florida Cancer Specialists & Research Institute (FCS) offers patients access to more clinical trials than any private oncology practice in Florida. Over the past 5 years, the majority of new cancer drugs approved for use in the U.S. were studied in clinical trials with Florida Cancer Specialists participation.* Trained in such prestigious medical schools and research institutes as Duke, Stanford, Harvard, Emory, MD Anderson, and Memorial Sloan Kettering, our physicians are consistently ranked nationally as Top Doctors by U.S. News & World Report.
Florida Cancer Specialists has built a national reputation for excellence that is reflected in exceptional and compassionate patient care, driven by innovative clinical research, cutting-edge technologies, and advanced treatments, including targeted therapies, genomic-based treatment, and immunotherapy. Our values are embodied by our outstanding team of highly trained and dedicated physicians, clinicians, and staff.
*Prior to approval
Attachment
